Consumer Healthcare Products Association (2012) Rx-toOTC Switch. http://www.chpa-info.org/scienceregulatory/Switch_SR.aspx
 Freudenheim, M. (2003) Claritin’s price falls, but drug costs more. The New York Times.
 Goldman, D.P., Joyce, G.F., et al. (2007) Prescription drug cost sharing: Associations with medication and medical utilization and spending and health. JAMA, 298, 61-69.
 Pierce, J.P. and Gilpin, E.A. (2002) Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking. JAMA, 288, 1260-1264.
 Reed, M.B., et al. (2005) The effect of over-the-counter sales of the nicotine patch and nicotine gum on smoking cessation in California. Cancer Epidemiology, Biomarkers & Prevention, 14, 2131-2136. http://dx.doi.org/10.1158/1055-9965.EPI-04-0919
 Moreau, C., Bajos, N. and Trussell, J. (2006). The impact of pharmacy access to emergency contraceptive pills in France. Contraception, 73, 602-608. http://dx.doi.org/10.1016/j.contraception.2006.01.012
 Sood, N., et al. (2008) Potential effects of introducing behind the counter drugs. RAND Working Paper.
 Sood, N., Sun, E., et al. (2012). Behind-the-counter statins: A silver bullet for reducing costs and increasing access? Health Services Research, 47, 174-187. http://dx.doi.org/10.1111/j.1475-6773.2011.01315.x
 Gurwitz, J.H., McLaughlin, T.J., et al. (1995). The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: The case of vaginal antifungal products. Health Services Research, 30, 672-685.
 Sullivan, P.W., Nair, K.V., et al. (2005) The effect of the Rx-to-OTC switch of loratadine and changes in prescription drug benefits on utilization and cost of therapy. American Journal of Managed Care, 11, 374-382.
 Furler, M.D., Rolnick, M.S., et al. (2002) Cost impact of switching histamine(2)-receptor antagonists to nonprescription status. The Annals of Pharmacotherapy, 36, 1135-1141. http://dx.doi.org/10.1345/aph.1A231
 Filion, K., et al. (2007) The impact of over-the-counter simvastatin on the number of statin prescriptions in the United Kingdom: A view from the general practice research database. Pharmacology and Drug Safety, 16, 1-4. http://dx.doi.org/10.1002/pds.1314
 Walker, R. and Hinchliffe, A. (2010) Prescribing and sale of ophthalmic chloramphenicol following reclassification to over-the-counter availability. International Journal of Pharmacy Practice, 18, 269-274. http://dx.doi.org/10.1111/ijpp.18.05.00046.x
 Sullivan, P.W., Follin, S.L., et al. (2003) Transitioning the second-generation antihistamines to over-the-counter status: A cost-effectiveness analysis. Medical Care, 41, 1382-1395. http://dx.doi.org/10.1097/01.MLR.0000100584.18276.C4
 Stead, L.F., et al. (2008) Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews, 1, Article ID: CD000146. http://dx.doi.org/10.1002/14651858.CD000146.pub3
 Raymond, E.G., Trussell, J., et al. (2007). Population effect of increased access to emergency contraceptive pills: A systematic review. Obstetrics & Gynecology, 109, 181-188. http://dx.doi.org/10.1097/01.AOG.0000250904.06923.4a
 Polis, C.B., Schaffer, K., et al. (2007). Advance provision of emergency contraception for pregnancy prevention: A meta-analysis. Obstetrics & Gynecology, 110, 1379-1388. http://dx.doi.org/10.1097/01.AOG.0000295603.84568.f6
 Lakdawalla, D., et al. (2006) Intellectual property and marketing. NBER Working Paper.
 Brass, E.P. (2004) Consumer behavior in the setting of over-the-counter statin availability: Lessons from the consumer use study of OTC Mevacor. American Journal of Cardiology, 94, 22F-29F. http://dx.doi.org/10.1016/j.amjcard.2004.07.051
 Melin, J.M., Struble, W.E., et al. (2004) A consumer use study of over-the-counter lovastatin (CUSTOM). American Journal of Cardiology, 94, 1243-1248. http://dx.doi.org/10.1016/j.amjcard.2004.08.007
 Brass, E.P., et al. (2008) Can consumers self-select for appropriate use of an over-the-counter statin? The self evaluation of Lovastatin to enhance cholesterol treatment study. American Journal of Cardiology, 101, 1448-1455. http://dx.doi.org/10.1016/j.amjcard.2008.01.020
 Kline and Company (2010) Rx-to-OTC Forecasts USA 2010. Kline & Company, Inc., Report no. #Y406C. http://www.klinegroup.com/reports/brochures/y406c/brochure.pdf
 Brass, E.P., et al. (2006) Potential impact on cardiovascular public health of over-the-counter statin availability. American Journal of Cardiology, 97, 851-856. http://dx.doi.org/10.1016/j.amjcard.2005.10.022
 Straka, R., et al. (2007) Economic impacts attributable to the early clinical benefit of atorvastatin therapy—A US managed care perspective. Current Medical Research and Opinion, 23, 1517-1529. http://dx.doi.org/10.1185/030079907X199808
 Cardozo, L., et al. (2010) The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine, extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. British Journal of Urology International, 106, 506-514. http://dx.doi.org/10.1111/j.1464-410X.2009.09160.x
 Clemens, J. (2011) Factors associated with work productivity impairment in subjects with overactive bladder. Presentation, AMCP 23rd Annual Meeting, Minneapolis, 27-29 April 2011.
 US Census Bureau (2010) Income, poverty, and health insurance coverage in the United States: 2009. Bureau of Labor Statistics, Labor Force Participation Rate Series.
 Lipton, R., et al. (2007) Migraine prevalence, disease burden, and the need for preventative therapy. Neurology, 68, 343-350. http://dx.doi.org/10.1212/01.wnl.0000252808.97649.21
 Hu, X., et al. (1999) Burden of migraine in the United States—Disability and economic costs. Archives of Internal Medicine, 159, 813-818. http://dx.doi.org/10.1001/archinte.159.8.813
 Lipton, R., et al. (2002) Migraine in the United States: Epidemiology and patterns of access to care. Neurology, 58, 885-894. http://dx.doi.org/10.1212/WNL.58.6.885
 Cambpell, N., et al. (2012) Internet-ordered viagra (sildenafil citrate) is rarely genuine. Presentation, American Urological Association 2012 Annual Meeting, Atlanta, 19-23 May 2012.
 Jackson, G., et al. (2010) Counterfeit phosphodisterase type 5 inhibitors pose significant safety risks. International Journal of Clinical Practice, 64, 497-504. http://dx.doi.org/10.1111/j.1742-1241.2009.02328.x
 Smith, K. and Roberts, M. (2000) The Cost-Effectiveness of Sildenafil. The Annals of Internal Medicine, 132, 933-937. http://dx.doi.org/10.7326/0003-4819-132-12-200006200-00002
 Shaw, M.J., Fendrick, A.M., et al. (2001) Self-reported effectiveness and physician consultation rate in users of over-the-counter histamine-2 receptor antagonists. The American Journal of Gastroenterologyl, 96, 673-676. http://dx.doi.org/10.1111/j.1572-0241.2001.03602.x